ENMD-2076

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：ENMD-2076	Purity：98% min
CAS NO：934353-76-1	Solubility：DMSO : ≥ 31 mg/mL (82.56 mM)
Molecular Formula：C₂₁H₂₅N₇	Package：Package according to customer requirements
Molecular Weight：375.470	Storage：Store at -20℃

Quality control

Remarks

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers.

CSF-1R Inhibitors Related Products:

GW2580; Pazopanib; Pazopanib HCl; Linifanib; ENMD-2076 Tartrate; OSI-930; Agerafenib; Ki20227; PLX5622; Pexidartinib; Pexidartinib HCL; Aprepitant; Erdafitinib; BLZ945

References

[1]. Fletcher GC, et al. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther. 2011 Jan;10(1):126-37.

[2]. Wang X, et al. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol. 2010 Aug;150(3):313-25.